Overcoming chemotherapy resistance

First-in-class cancer treatment

Scandion Oncology will provide new cancer treatments to help overcome chemotherapy resistance for thousands of patients.

Detailed analyses estimate the market to be more than EUR 4 billion annually.

Fast and low-cost track to results

We aim to conclude one Phase II trial within the next two years. Upon conclusion of the Phase II trial, we will be ready to consider exit or partner options.

Forceful and attractive patents

Scandion Oncology has a forceful patent portfolio lasting until 2037. The patents could be attractive for big pharma to combine with existing cancer treatments.

Pipeline

Scandion Oncology has two promising compounds in the pipeline. SCO-101, our most advanced lead candidate, is in clinical Phase I and II studies and SCO-201 is in preclinical testing. We expect to deliver proof-of-concept with SCO-101 in 2022. Scandion Oncology is building a pipeline of drugs that can revert anti-cancer drug resistance through different mechanisms. The aim is to increasingly broaden the offering of medicines able to combat anti-cancer drug resistance. 

Clinical Trials

Our first-in-class lead compound SCO-101 has been shown to enhance the effect of certain standard chemotherapies when given in combination. Scandion Oncology has two programs in clinical development with SCO-101. The most advanced program, CORIST, for the treatment of drug resistant metastatic colorectal cancer is in clinical Phase II studies. The second program, PANTAX, for the treatment of inoperable or metastatic pancreatic cancer is in clinical Phase Ib studies.

Investors

Detailed analyses suggest the market for Scandion Oncology’s products to be more than EUR 4 billion annually.

We believe our programs could be attractive for various pharmaceutical companies to combine with their anti-cancer treatments.